newsGP - PBAC supports ‘long overdue’ expansion to ADHD drug access

The PBAC has recommended expanding PBS access to non-stimulant ADHD medications, atomoxetine and guanfacine, for patients who have not adequately responded to stimulant therapy, and allowing GPs to initiate treatment. This move is seen as long overdue and will improve access and affordability for patients, while providing GPs with greater flexibility in managing ADHD. The changes aim to align PBS access with current clinical guidelines and address long wait times and increasing demand for ADHD care.

Read at Royal Australian College of General Practitioners (RACGP)

All articles from 21 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.